X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs ABBOTT INDIA - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. ABBOTT INDIA FRESENIUS KABI ONCO./
ABBOTT INDIA
 
P/E (TTM) x 22.1 35.9 61.6% View Chart
P/BV x 3.1 9.3 33.5% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 FRESENIUS KABI ONCO.   ABBOTT INDIA
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
ABBOTT INDIA
Mar-18
FRESENIUS KABI ONCO./
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs1766,110 2.9%   
Low Rs793,996 2.0%   
Sales per share (Unadj.) Rs37.71,552.2 2.4%  
Earnings per share (Unadj.) Rs5.1188.8 2.7%  
Cash flow per share (Unadj.) Rs6.7196.4 3.4%  
Dividends per share (Unadj.) Rs055.00 0.0%  
Dividend yield (eoy) %01.1 0.0%  
Book value per share (Unadj.) Rs42.5796.6 5.3%  
Shares outstanding (eoy) m158.2321.25 744.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.43.3 103.7%   
Avg P/E ratio x25.026.8 93.4%  
P/CF ratio (eoy) x18.925.7 73.6%  
Price / Book Value ratio x3.06.3 47.2%  
Dividend payout %029.1 0.0%   
Avg Mkt Cap Rs m20,135107,376 18.8%   
No. of employees `0001.23.3 34.7%   
Total wages/salary Rs m7033,937 17.9%   
Avg. sales/employee Rs Th5,176.29,929.3 52.1%   
Avg. wages/employee Rs Th610.41,185.1 51.5%   
Avg. net profit/employee Rs Th699.61,207.7 57.9%   
INCOME DATA
Net Sales Rs m5,96332,985 18.1%  
Other income Rs m181,170 1.5%   
Total revenues Rs m5,98134,155 17.5%   
Gross profit Rs m1,4305,245 27.3%  
Depreciation Rs m258162 159.3%   
Interest Rs m-2638 -68.1%   
Profit before tax Rs m1,2166,215 19.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m3422,203 15.5%   
Profit after tax Rs m8064,012 20.1%  
Gross profit margin %24.015.9 150.8%  
Effective tax rate %28.135.4 79.4%   
Net profit margin %13.512.2 111.1%  
BALANCE SHEET DATA
Current assets Rs m5,10222,655 22.5%   
Current liabilities Rs m2,3856,681 35.7%   
Net working cap to sales %45.648.4 94.1%  
Current ratio x2.13.4 63.1%  
Inventory Days Days15065 231.6%  
Debtors Days Days11329 388.6%  
Net fixed assets Rs m5,148835 616.2%   
Share capital Rs m158213 74.4%   
"Free" reserves Rs m6,55616,715 39.2%   
Net worth Rs m6,73216,928 39.8%   
Long term debt Rs m9520-   
Total assets Rs m10,38824,162 43.0%  
Interest coverage x-45.8163.7 -28.0%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.61.4 42.0%   
Return on assets %7.516.8 44.8%  
Return on equity %12.023.7 50.5%  
Return on capital %14.636.9 39.5%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Exports (fob) Rs m4,441NA-   
Imports (cif) Rs m1,477NA-   
Fx inflow Rs m5,298369 1,437.5%   
Fx outflow Rs m1,7723,807 46.6%   
Net fx Rs m3,525-3,438 -102.5%   
CASH FLOW
From Operations Rs m1,2741,527 83.4%  
From Investments Rs m-1,204-2,148 56.1%  
From Financial Activity Rs m-196-1,024 19.1%  
Net Cashflow Rs m-126-1,646 7.7%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 81.0 75.0 108.0%  
Indian inst/Mut Fund % 0.3 7.9 3.8%  
FIIs % 9.6 0.1 9,600.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 17.1 53.2%  
Shareholders   42,599 18,270 233.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   ALEMBIC PHARMA  STRIDES PHARMA SCIENCE  FDC LTD.  ASTRAZENECA PHARMA  BIOCON   

Compare FRESENIUS KABI ONCO. With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

US China Trade War Escalations and Election Results: Volatility Set to Rule(Podcast)

India could be the latest direct victim of the US-China trade war. The increasing escalations have already slowed down global growth.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (3QFY19); Net Profit Up 1.4% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 1.4% YoY). Sales on the other hand came in at Rs 9 bn (up 7.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (2QFY19); Net Profit Up 0.1% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 0.1% YoY). Sales on the other hand came in at Rs 10 bn (up 5.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY19); Net Profit Up 70.8% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, ABBOTT INDIA has posted a net profit of Rs 824 m (up 70.8% YoY). Sales on the other hand came in at Rs 8 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY18); Net Profit Up 137.9% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 137.9% YoY). Sales on the other hand came in at Rs 8 bn (up 10.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

These Dividend Stocks Could Boost Your Returns Better Than You Can Imagine(Profit Hunter)

May 7, 2019

The art of dividend investing is a lot more than investing in companies with high dividend payouts or stocks with high dividend yields...

Limited Upside, Higher Downside(The Honest Truth)

May 6, 2019

The market's irrational reaction may present opportunities for a limited period of time.

3 Indian Stocks Replicating Amazon's Successful Strategy(The 5 Minute Wrapup)

May 10, 2019

The one critical element that has made Amazon a force to reckon with...

A Simple Checklist for Picking Great Dividend Stocks(Profit Hunter)

May 9, 2019

A filtered, neat list of high-dividend stocks with all this dirty work already done for you.

My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

May 16, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 5-YR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS